Multiple Sclerosis

Two abstracts presented at a recent multiple sclerosis meeting examined depression in pregnancy and pregnancy outcomes in ozanimod trials.

The researchers noted that although it is known that pregnancy is linked to reduced MS activity, the effect of pregnancy before MS diagnosis is unclear.

Differences in clinical and demographic characteristics between men and women with multiple sclerosis (MS) are more prevalent regarding disease course than they are when stratifying by sex.

Rebooting the immune system is an exciting approach, noted John Corboy, MD, professor of neurology, University of Colorado Denver, School of Medicine, and co-director of the Rocky Mountain MS Center at Anschutz Medical Campus.

Older individuals need medications that focus on effects inside the nervous system, explained John Corboy, MD, of University of Colorado Denver, School of Medicine, and Rocky Mountain MS Center at Anschutz Medical Campus.

Research on the long-term use of ozanimod in relapsing forms of multiple sclerosis (MS) has shown the treatment is effective with no new safety concerns.

A recent study explored whether interrupting disease-modifying therapies (DMTs) because of pregnancy leads to increased levels of a specific biomarker of neuroaxonal injury seen in MS.

Tailoring treatment to individual patients is the ultimate goal in the complex decision-making process of managing progressive multiple sclerosis (MS), noted Burcu Zeydan, MD, assistant professor of neurology, assistant professor of radiology, Mayo Clinic.

The results were shared as part of the MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting, which is concluding Saturday with a special session about coronavirus disease 2019 (COVID-19).

Patients with multiple sclerosis (MS) reported higher rates of harassment and criticism in the workplace than their healthy counterparts, even after informing employers and coworkers about their diagnosis.

Relapse at an older age can significantly contribute to a worsening of multiple sclerosis (MS), explained Burcu Zeyda, MD, assistant professor of neurology, assistant professor of radiology, at Mayo Clinic.

Emerging data is showing that treatment within 6 months of presentation of multiple sclerosis (MS) is ideal, explained Patricia K. Coyle, MD, of Stony Brook University Neurosciences Institute.

Results of a combined training program in 17 patients with multiple sclerosis indicate patients reap benefits from daily activities like walking or sitting-to-standing, and show the program reduces the dual-task cost of performing cognitive tasks while walking.

The authors suggest that recognizing the possible link may help identify patients at greater risk, although they do caution that larger studies are needed.

A small study says that gloves with sensors could measure impairments in hand function and may have advantages over standard methods.

Patients were more likely to report more relapses of multiple sclerosis than physicians.

Adherence to multiple sclerosis (MS) therapy is linked with improved clinical outcomes, better quality of life, lower health care costs, and other benefits.

For multiple sclerosis, the therapy will be sold as Kesimpta by Novartis; it is administered by patients once a month through the Sensoready autoinjector pen.

A combination of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) relieved certain neurophysiological symptoms affecting patients with secondary progressive multiple sclerosis (MS).

Certain aspects of satisfaction with multiple sclerosis (MS) treatment can impact health-related quality of life (HRQOL).

The thalamus is among the first brain areas to atrophy in multiple sclerosis (MS); this study wanted to know if measuring this loss can predict future disability.

A new analysis offers insights into how ozanimod works in patients with relapsing multiple sclerosis, as well as the impact of higher dosage.

A new study helps make clear what’s happening in the visual systems of patients with pediatric onset multiple sclerosis.

Alemtuzumab did not appear to negatively impact pregnancy outcomes in women who took the therapy for relapsing-remitting multiple sclerosis prior to becoming pregnant.